TAE684 (NVP-TAE684)

Catalog No.S1108

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

TAE684 (NVP-TAE684) Chemical Structure

TAE684 (NVP-TAE684) Chemical Structure
Molecular Weight: 614.2

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

ALK Inhibitors with Unique Features

  • Non-specific ALK Inhibitor

    GSK1838705A IGF-1R, IC50=2.0 nM; IR, IC50=1.6 nM, ALK, IC50=0.5 nM.

  • Most Potent ALK Inhibitor

    Ceritinib (LDK378) ALK, IC50=0.2 nM.

  • FDA-approved ALK Inhibitor

    Crizotinib (PF-02341066) Approved by FDA for non-small cell lung carcinoma (NSCLC).

  • Newest ALK Inhibitor

    ASP3026 Novel and selective inhibitor for ALK with IC50 of 3.5 nM.

Product Information

  • Compare ALK Inhibitors
    Compare ALK Products
  • Research Area
  • TAE684 (NVP-TAE684) Mechanism

Product Description

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets ALK [1]
(Cell-free assay)
IC50 3 nM
In vitro TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SCC-3M4XWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwMECwNFYxOyEQvF2=MmDHV2FPT0WU
SF539MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTBwMECwOVY1KM7:TR?=MnLuV2FPT0WU
DELNF;JN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLmNVVKSzVyPUCuNFAxQTJ5IN88US=>NWHpbG1SW0GQR1XS
NB1NXHrcJZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nHW2lEPTB;MD6wNFE3OiEQvF2=NHn6[lRUSU6JRWK=
SRNWnFUnVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjrTWM2OD1yLkCwNlc4KM7:TR?=MVfTRW5ITVJ?
KARPAS-299MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnERlZLUUN3ME2wMlAzOzh2IN88US=>MmfjV2FPT0WU
MHH-CALL-2NUj5dY82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTBwMEK5OVIh|ryPMWTTRW5ITVJ?
SU-DHL-1M2rNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTBwMES4OlUh|ryPMoDPV2FPT0WU
A4-FukM3rk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DqRWlEPTB;MD6wOVU3PSEQvF2=NUG5eodEW0GQR1XS
EW-1M4\Tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHoPVBLUUN3ME2wMlExOjV4IN88US=>NWGxS2FzW0GQR1XS
NOS-1M2\CWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkP3TWM2OD1yLkGwNlk1KM7:TR?=MkTmV2FPT0WU
EW-16MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVO1SoV6UUN3ME2wMlExPTZ6IN88US=>NF7JbpdUSU6JRWK=
TE-11M2Ptbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwMU[wPVYh|ryPMormV2FPT0WU
SW982M4TlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTBwMU[0O|gh|ryPNXfrXFN5W0GQR1XS
LAN-6NFzsfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTBwMUe0OFMh|ryPNVPhO5loW0GQR1XS
MZ1-PCMn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXyyTWpoUUN3ME2wMlE4QDN3IN88US=>NX;JRW5jW0GQR1XS
KS-1NF;nU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mor1TWM2OD1yLkG5N|Q{KM7:TR?=MWTTRW5ITVJ?
PSN1MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLkTWM2OD1yLkG5OlMyKM7:TR?=MYLTRW5ITVJ?
LC-2-adMo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTBwMUm2PVIh|ryPNGHXe5ZUSU6JRWK=
COLO-320-HSRNF[4[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlm3TWM2OD1yLkG5O|c3KM7:TR?=NUm5SpFtW0GQR1XS
OPM-2MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjzZWtKSzVyPUCuNlI3PjlizszNNVrsUHVlW0GQR1XS
SK-NEP-1MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTBwMkO1NlQh|ryPMX3TRW5ITVJ?
ALL-POM3;qfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTBwMkS1NlQh|ryPNGW0cI5USU6JRWK=
CMKMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjKWGpKSzVyPUCuNlU2OyEQvF2=NEXURmxUSU6JRWK=
NCI-H1648NVL2RVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXze2RKSzVyPUCuNlc5PTVizszNNUnE[|ZxW0GQR1XS
SIG-M5NH\BVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jKfGlEPTB;MD6yPVE2QSEQvF2=M4q0WnNCVkeHUh?=
TGBC24TKBNFfBc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTBwM{CyNVgh|ryPM1TOZXNCVkeHUh?=
DOHH-2NX7nPGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTBwM{GyNFQh|ryPMmTzV2FPT0WU
NB69MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVz3V4FpUUN3ME2wMlMyPzh5IN88US=>MoO3V2FPT0WU
MFH-inoM1\yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTBwM{K1NlMh|ryPNWi2ZnB3W0GQR1XS
KP-N-RT-BM-1NHiyWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLLOI14UUN3ME2wMlM{OTJ|IN88US=>NXPnboZbW0GQR1XS
MONO-MAC-6M3m2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2CzSGlEPTB;MD6zN|I6OSEQvF2=MYrTRW5ITVJ?
ATN-1M1K3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DqXGlEPTB;MD6zN|MxOyEQvF2=NXjhZ2lFW0GQR1XS
NTERA-S-cl-D1NIXQUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHtTVJtUUN3ME2wMlM{Ozl4IN88US=>NV20e|k6W0GQR1XS
L-540M1TYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTVTWM2OD1yLkO2PVg5KM7:TR?=M{O0UXNCVkeHUh?=
GB-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXRO4ZKSzVyPUCuN|g5PjdizszNNGHWbotUSU6JRWK=
MV-4-11MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTETWM2OD1yLkO5OFQ3KM7:TR?=MWfTRW5ITVJ?
KG-1NYLj[pFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvOTWM2OD1yLkO5OVYyKM7:TR?=MXjTRW5ITVJ?
OVCAR-4NHjhbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlWyTWM2OD1yLkSwOVY6KM7:TR?=MlPSV2FPT0WU
NEC8NWnJZVZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTBwNEGyPVIh|ryPMlK0V2FPT0WU
SK-MM-2M2nPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlflTWM2OD1yLkSxOlA6KM7:TR?=NH3BZVVUSU6JRWK=
TE-8M{LKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PIdWlEPTB;MD60Nlg5KM7:TR?=NFnTcFZUSU6JRWK=
697NYfyfIRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoO5TWM2OD1yLkSzNlE2KM7:TR?=NITzVI9USU6JRWK=
NB14MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFywcXFKSzVyPUCuOFM5OjZizszNM2D4S3NCVkeHUh?=
GDM-1NWnzfJlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXCNmZKSzVyPUCuOFcyOTZizszNNVzUW4E3W0GQR1XS
HUTU-80M{L6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\5[mlEPTB;MD60O|M4PSEQvF2=MWHTRW5ITVJ?
HL-60MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXhOXlKSzVyPUCuOFgyPDJizszNNXHWOHptW0GQR1XS
OCI-AML2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTBwNEizNlgh|ryPM1yzNXNCVkeHUh?=
ML-2NITNVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mly3TWM2OD1yLkS5NFMyKM7:TR?=NIXZZWZUSU6JRWK=
ES4NVLIXYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fjc2lEPTB;MD60PVExQSEQvF2=MYTTRW5ITVJ?
NCI-H747M3;Cfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfldYRKSzVyPUCuOFk5QSEQvF2=NIDEWlZUSU6JRWK=
RL95-2NHP4fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYKxWFJ2UUN3ME2wMlUxOTF{IN88US=>Mn[0V2FPT0WU
TE-15M13MSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3[1Z2lEPTB;MD61NVEzPCEQvF2=NX\oVYlCW0GQR1XS
TE-12MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHyfpFKSzVyPUCuOVM{PDlizszNNXvGXoxHW0GQR1XS
LB1047-RCCMnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jifmlEPTB;MD61OFU1QSEQvF2=NUTKcWJTW0GQR1XS
LB831-BLCNXzJV49zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTBwNUWwNlMh|ryPMn\tV2FPT0WU
NCI-H1355NY\ySZoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3wN49HUUN3ME2wMlU2OTh2IN88US=>MVnTRW5ITVJ?
CTV-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTUWFhKSzVyPUCuOVU3OjRizszNMmDjV2FPT0WU
RXF393MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTBwNUW3PVQh|ryPNFf3TIlUSU6JRWK=
SW872MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrROHRKSzVyPUCuOVY4OjRizszNMnzmV2FPT0WU
MPP-89MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\LfmlEPTB;MD61O|g5PCEQvF2=MWjTRW5ITVJ?
RPMI-8226NI\5Wo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17kPGlEPTB;MD62N|UzPiEQvF2=M{nzZnNCVkeHUh?=
LS-1034NYrrPYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGH5WoFKSzVyPUCuOlM2QCEQvF2=NFXqPY1USU6JRWK=
SJSA-1MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTBwNkO3NlUh|ryPMWLTRW5ITVJ?
HOP-62NF\wSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;RUWlEPTB;MD62OVA{OyEQvF2=MljhV2FPT0WU
KGNMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHBXHFKSzVyPUCuOlYyPjhizszNNFrOO|JUSU6JRWK=
D-336MGNYS1eY9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrGUYhKSzVyPUCuOlYyPjlizszNNYLm[WcyW0GQR1XS
LS-411NMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTBwNke0OlIh|ryPM{O4e3NCVkeHUh?=
TE-1NEHnXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnHTWM2OD1yLk[5NFc1KM7:TR?=NEDsRpNUSU6JRWK=
LB996-RCCNFm1VIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTBwNkmzPFkh|ryPMWjTRW5ITVJ?
TE-10NHzJ[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\nfWlEPTB;MD63NVQ6PiEQvF2=NYSxOHB{W0GQR1XS
NCI-SNU-16MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\zOGlEPTB;MD63NlY3PCEQvF2=NWr5T4dDW0GQR1XS
ES8MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2[yRmlEPTB;MD63OFk4PSEQvF2=Mk\RV2FPT0WU
COLO-800NHWxSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2GzPWlEPTB;MD63OlY6PSEQvF2=M3HhUHNCVkeHUh?=
ES6NI\2cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PZfmlEPTB;MD63O|U2QSEQvF2=MnXWV2FPT0WU
L-363NGKzOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnkRnBKSzVyPUCuPFI{PzVizszNNYDGfWROW0GQR1XS
NMC-G1NYH5XYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTBwOEOyN|Mh|ryPMYfTRW5ITVJ?
LU-134-AMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\qOphKSzVyPUCuPFM6OTJizszNM1TrT3NCVkeHUh?=
SF268MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFSzd4VKSzVyPUCuPFQxPDJizszNNHv6dlBUSU6JRWK=
KARPAS-45Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjpZ3JvUUN3ME2wMlg1OjZ|IN88US=>NHfOcJJUSU6JRWK=
TGWNWnRdWtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDLVGk6UUN3ME2wMlg2QDZ|IN88US=>MYrTRW5ITVJ?
CHP-126NU[yVFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvHTWM2OD1yLki1PVU4KM7:TR?=NIfF[ZpUSU6JRWK=
MOLT-16MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTBwOEe1PFkh|ryPNUHB[JliW0GQR1XS
LB771-HNCNITWeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{i1SWlEPTB;MD64PVc2PyEQvF2=NHjvN|NUSU6JRWK=
NALM-6NGDGTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGO1VlhKSzVyPUCuPVA4OzlizszNNV7YTYdvW0GQR1XS
GCIYMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTBwOUW1NlYh|ryPMV\TRW5ITVJ?
IST-MES1NGTmbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jKUmlEPTB;MD65PFgzPCEQvF2=M{PiPHNCVkeHUh?=
LB2241-RCCNIL4R4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{j3W2lEPTB;MD65PFg1KM7:TR?=NWjHc4xjW0GQR1XS
BL-70NXvUfGV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTBwOUm1N|Uh|ryPNED6VJhUSU6JRWK=
NB17NGXhRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PqV2lEPTB;MT6wNFY{QSEQvF2=MnThV2FPT0WU
LXF-289MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{W0d2lEPTB;MT6wN|A4PiEQvF2=MoHQV2FPT0WU
TK10MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfqd5hKSzVyPUGuNFUxPjNizszNNWLZXXg2W0GQR1XS
K5MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnEdoVKSzVyPUGuNFYzPzRizszNM3G5bnNCVkeHUh?=
NCI-H716NFjN[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfOTWM2OD1zLkC3NlU6KM7:TR?=NFHZTGpUSU6JRWK=
HCE-TNHW0bmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvNTWM2OD1zLkC4PFE6KM7:TR?=M4DrN3NCVkeHUh?=
GI-1NEDXdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPaOYpKSzVyPUGuNFk4QThizszNMmHyV2FPT0WU
KARPAS-422MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTFwMUCwNlIh|ryPNXnMNYhOW0GQR1XS
TE-9M1zhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIP0VIlKSzVyPUGuNVE{OjhizszNNYHmW4JMW0GQR1XS
SF126NEHzVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTFwMUG1Olgh|ryPMWjTRW5ITVJ?
BB30-HNCNH;OZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jPXmlEPTB;MT6xN|EyOiEQvF2=M4DCTnNCVkeHUh?=
NCI-H1304M{HTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;mepc6UUN3ME2xMlE{OzN6IN88US=>NGq1b4lUSU6JRWK=
HELM12x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrBT3ZYUUN3ME2xMlE1QDl3IN88US=>M1f5d3NCVkeHUh?=
HAL-01M{[1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDSeIZ[UUN3ME2xMlE2Ojh|IN88US=>NWPnPJZHW0GQR1XS
SK-LMS-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7iXY5UUUN3ME2xMlE2QTd2IN88US=>M4XxN3NCVkeHUh?=
SW954MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXZU3dKSzVyPUGuNVk2PjdizszNM1;MPXNCVkeHUh?=
D-283MEDNFTmeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LQ[WlEPTB;MT6yNlM4QSEQvF2=NVTIfnZHW0GQR1XS
NCI-H1882NFfjfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTFwMkO4PUDPxE1?M{\aXnNCVkeHUh?=
GI-ME-NMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTFwMkWyNFgh|ryPM{TPSHNCVkeHUh?=
SK-PN-DWNYq0[YgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvuTWM2OD1zLkK2N|Q5KM7:TR?=MXPTRW5ITVJ?
C2BBe1NIr0ZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTFwMkmxNVch|ryPM2X1TnNCVkeHUh?=
A704MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\1VmlEPTB;MT6zNlY5QSEQvF2=NEnDdVdUSU6JRWK=
KALS-1NH3TTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvzToVJUUN3ME2xMlM1ODhizszNMWnTRW5ITVJ?
ETK-1M4DSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljNTWM2OD1zLkO0OFg6KM7:TR?=MlLsV2FPT0WU
LB647-SCLCNISwdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLTTWM2OD1zLkO0PVg3KM7:TR?=NH;Je|VUSU6JRWK=
OCUB-MNHmzPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGr0SlBKSzVyPUGuN|YyPDNizszNMWnTRW5ITVJ?
NCI-H720MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjGUYZ7UUN3ME2xMlM3Ozd6IN88US=>NFv5WnRUSU6JRWK=
NB13M4G2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTFwM{eyPVMh|ryPNEj1bnBUSU6JRWK=
GR-STMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTQd2t{UUN3ME2xMlM5PzV5IN88US=>MVjTRW5ITVJ?
DU-4475MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLnNZJsUUN3ME2xMlQ2QDV|IN88US=>NWTWNmZwW0GQR1XS
HCC2157NFjpXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{WxVGlEPTB;MT60OlY2QSEQvF2=NXS5O2o4W0GQR1XS
RKONXv2[48yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17YZWlEPTB;MT60PVkzOiEQvF2=MW\TRW5ITVJ?
LS-123NH;6N4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUW2PVVsUUN3ME2xMlUyPTl2IN88US=>NUfoXo1XW0GQR1XS
NCI-H69NFPVO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTTTWM2OD1zLkW1PFEyKM7:TR?=MlPZV2FPT0WU
SW962NFXQUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DBZ2lEPTB;MT61OlE{KM7:TR?=Mkm4V2FPT0WU
PF-382NV[wd|M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmntTWM2OD1zLkW2PVYh|ryPM1LDPHNCVkeHUh?=
A101DMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH22T45KSzVyPUGuOVcyOTNizszNMlHSV2FPT0WU
NB10M4rYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTFwNUezPVIh|ryPM3vCVHNCVkeHUh?=
NB5NVfv[XZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTFwNUi0O|Yh|ryPNWSxUHdoW0GQR1XS
HCE-4M1yyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVX6OnNYUUN3ME2xMlYxQDVizszNNVvUW|V3W0GQR1XS
HT-144NY\iXoZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{OxfGlEPTB;MT62N|E6KM7:TR?=M{DsR3NCVkeHUh?=
NCI-H524NX62XmJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXadFBKSzVyPUGuOlQ{ODdizszNNXzveGpvW0GQR1XS
NKM-1NWDhZYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorQTWM2OD1zLk[4OlYh|ryPNX\sVVFxW0GQR1XS
KURAMOCHIMmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTFwNkm1O|Mh|ryPM3TrNnNCVkeHUh?=
NCI-H187M2r3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nSSGlEPTB;MT63NFA{PiEQvF2=NYH2UmJYW0GQR1XS
U-266MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDhUYFkUUN3ME2xMlc{QDR{IN88US=>MnvQV2FPT0WU
BL-41NXPGUIl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTFwN{[yO|Ih|ryPMn;LV2FPT0WU
SK-N-DZM3vvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTFwN{izNFkh|ryPNHLFN2lUSU6JRWK=
DaudiM2OySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4G4c2lEPTB;MT63PFk3PyEQvF2=NH\qNJhUSU6JRWK=
CPC-NNIjtO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTse21RUUN3ME2xMlg2ODl4IN88US=>MYPTRW5ITVJ?
EM-2M2j2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTFwOEWxJO69VQ>?M{LZN3NCVkeHUh?=
HCC1187NWXwRmp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjCR2NyUUN3ME2xMlg3OjRzIN88US=>NGTMSY1USU6JRWK=
LP-1NULWOYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTFwOEexOFMh|ryPM{HITHNCVkeHUh?=
CAS-1NXr4OGY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnrR4lDUUN3ME2xMlk5Ojl7IN88US=>MVzTRW5ITVJ?
NB7NFnWfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml25TWM2OD1{LkCwOVU2KM7:TR?=MUDTRW5ITVJ?
VA-ES-BJM3\0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTJwMEG1NVMh|ryPNVv6Z3lvW0GQR1XS
SNU-C2BM2[3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjqRms{UUN3ME2yMlA{OzVzIN88US=>M3n6dnNCVkeHUh?=
LOXIMVINFTWbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\tb3FKSzVyPUKuNFY4QDZizszNMorEV2FPT0WU
NCI-H1581MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXK4PZNWUUN3ME2yMlEyPTV7IN88US=>M{PSWXNCVkeHUh?=
IST-SL2NVXwTHp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXv6[pdIUUN3ME2yMlEzPDR3IN88US=>MX3TRW5ITVJ?
NOMO-1M{SwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTJwMUe2PFMh|ryPM1fmbnNCVkeHUh?=
TE-6M3eze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTnTWM2OD1{LkG5NFUh|ryPM3zTVXNCVkeHUh?=
NCI-H526MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGL3PXNKSzVyPUKuNVkyPDFizszNMlzkV2FPT0WU
MSTO-211HMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3m3cmlEPTB;Mj6yNFA1OSEQvF2=M2GzXnNCVkeHUh?=
LS-513MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWL5dot5UUN3ME2yMlIzOjZ7IN88US=>Mmf2V2FPT0WU
NCI-SNU-1MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPuTWM2OD1{LkOzNlU3KM7:TR?=NIjQb4VUSU6JRWK=
BB65-RCCNFjFN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TnZ2lEPTB;Mj6zO|Q6OyEQvF2=NFvC[mNUSU6JRWK=
GT3TKBNHW3Z3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXS4[ZhXUUN3ME2yMlM6QTd{IN88US=>NXvPcYt1W0GQR1XS
OS-RC-2M3LSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlryTWM2OD1{LkSyN|QyKM7:TR?=M1HGXXNCVkeHUh?=
NCI-H2126NIDBb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\TTWM2OD1{LkSzOlc1KM7:TR?=NWPNd|JnW0GQR1XS
SK-UT-1M4D5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDrTWM2OD1{LkS3OFY4KM7:TR?=NFznc3JUSU6JRWK=
DMS-114NETLUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2qwRmlEPTB;Mj62NVUzPCEQvF2=MkDtV2FPT0WU
ONS-76NYizXFZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXj5cY03UUN3ME2yMlY{PjRzIN88US=>NF;PNXJUSU6JRWK=
8-MG-BAMorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;KSWlEPTB;Mj62OVQyPCEQvF2=MonDV2FPT0WU
BOKUMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4Xw[GlEPTB;Mj63Nlc3PCEQvF2=M4\OeXNCVkeHUh?=
LAMA-84MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\jbZlKSzVyPUKuO|k6OTJizszNMY\TRW5ITVJ?
ES1NYnabGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXq0fZI2UUN3ME2yMlgyQDB2IN88US=>MWfTRW5ITVJ?
NCI-H1395M3\iRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1P5bWlEPTB;Mj64NlAyOiEQvF2=NXP1VG9lW0GQR1XS
A388NInpXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnVTWM2OD1{Lkm2NVch|ryPMWTTRW5ITVJ?
NCCITNF24TmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\WO2lEPTB;Mz6wPFg3OiEQvF2=MVLTRW5ITVJ?
HD-MY-ZNH:3XJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPnTWM2OD1|LkGzNlA{KM7:TR?=MlfDV2FPT0WU
NCI-H510ANUiySnd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTNwMUi5OFMh|ryPMoS2V2FPT0WU
NCI-N87MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4r6eGlEPTB;Mz6yNFAzKM7:TR?=MU\TRW5ITVJ?
SCLC-21HMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTNwMk[4OVkh|ryPNGnpcFdUSU6JRWK=
SH-4NFX4OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2S0dWlEPTB;Mz6yPFc6PyEQvF2=MmXPV2FPT0WU
QIMR-WILM335Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33Ne2lEPTB;Mz6zNlg1QSEQvF2=NHiwU3BUSU6JRWK=
KM12NYP3UHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrnTWM2OD1|LkOzOVQ1KM7:TR?=NVvQWItWW0GQR1XS
ST486MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTNwNUO4PFMh|ryPMV7TRW5ITVJ?
HC-1NFHIR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXO5fGppUUN3ME2zMlYzODJ6IN88US=>NIPMNGhUSU6JRWK=
BV-173NFzPNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXMdGx7UUN3ME2zMlY1ODh6IN88US=>NUPGd3o6W0GQR1XS
EW-24MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7oTWM2OD1|Lk[2OFM1KM7:TR?=M1npWnNCVkeHUh?=
LU-65NYD6NpJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHNTYdKSzVyPUOuOlg4OSEQvF2=M4fXSnNCVkeHUh?=
ECC4Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LNN2lEPTB;Mz63O|U3KM7:TR?=M3zrPXNCVkeHUh?=
ARH-77NIPNd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTRwMUGwOlch|ryPM2POc3NCVkeHUh?=
BC-3MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPNTWM2OD12LkGzNFY5KM7:TR?=NW\QSWc3W0GQR1XS
SNB75MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPpb5RGUUN3ME20MlI3OTlizszNNUHaV|FtW0GQR1XS
MEG-01MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\qR4tKSzVyPUSuNlc1OTlizszNMoLwV2FPT0WU
NCI-H1417M3;hZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XFcmlEPTB;ND6yPFQ1OyEQvF2=Mn7MV2FPT0WU
MDA-MB-134-VIM1zqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTRwM{C2NFEh|ryPM1\VWnNCVkeHUh?=
BeckerMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDEdYxKSzVyPUSuOFc{OzZizszNMVzTRW5ITVJ?
DMS-153MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDWTWM2OD12Lk[2OFc2KM7:TR?=MYrTRW5ITVJ?
TGBC1TKBMkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFi1VlhKSzVyPUSuOlg2OTVizszNM2jDS3NCVkeHUh?=
EW-3Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEP4WnBKSzVyPUSuO|YzPDhizszNNFjS[ZJUSU6JRWK=
KE-37MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTRwOE[xPVYh|ryPMkjFV2FPT0WU
NCI-H23NYfsdYNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLuTWM2OD12Lki3NlI4KM7:TR?=MXzTRW5ITVJ?
MC116NH;oPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fFXGlEPTB;ND65OFEzPiEQvF2=M32wPXNCVkeHUh?=
NH-12M1P1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfBeYVKSzVyPUSuPVY1OzlizszNNVvzWIltW0GQR1XS
CTB-1M3LPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFe0V2VKSzVyPUSuPVc4OjFizszNNHHrRZRUSU6JRWK=
KM-H2M{XWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTVwMEWzNlMh|ryPM{DCbHNCVkeHUh?=
MOLT-4NWq2VINHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2q0UmlEPTB;NT6xNVg{KM7:TR?=NWHoTJJEW0GQR1XS
NCI-H2141MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;lTWM2OD13LkG0NlY5KM7:TR?=NHvmZWZUSU6JRWK=
EB-3MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvuRYpOUUN3ME21MlE4PTB2IN88US=>NF3FOolUSU6JRWK=
NCI-H1522M2TZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIntcpFKSzVyPUWuNlY{OjJizszNM13BS3NCVkeHUh?=
MRK-nu-1MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHwfGJ4UUN3ME21MlQ{PjN|IN88US=>MXzTRW5ITVJ?
no-11M3XoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlu2TWM2OD13LkS3NFg4KM7:TR?=M2DCVXNCVkeHUh?=
CESSMkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13vVWlEPTB;NT61PFA{PCEQvF2=MV\TRW5ITVJ?
KMOE-2MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\nTWM2OD13LkW4OlU6KM7:TR?=NXrLSWViW0GQR1XS
REHMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTZwMkW2NVgh|ryPMW\TRW5ITVJ?
KU812MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXOTWM2OD14LkSyO|kyKM7:TR?=MknlV2FPT0WU
SK-N-FIM2LwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXTTWM2OD14Lk[wOlc1KM7:TR?=NEHXdVBUSU6JRWK=
MMAC-SFM3rtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTHenluUUN3ME23MlA3PDl{IN88US=>MoT1V2FPT0WU
RCC10RGBNGCxNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLqUoVKSzVyPUeuNlI6PzdizszNMXzTRW5ITVJ?
NCI-H322MMkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;nTWM2OD15LkOzN|M2KM7:TR?=NFTkWmRUSU6JRWK=
NB6MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXWUYNlUUN3ME23MlU1QDl7IN88US=>MonKV2FPT0WU
MN-60NFvrZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPtTWM2OD15Lk[5NlE2KM7:TR?=MXjTRW5ITVJ?
NCI-H1092NFLyVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYO5b5ZMUUN3ME24MlAyPzN2IN88US=>NXm2enhMW0GQR1XS
EKVXNIHDT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRThwNEewOlYh|ryPNV\KR5pnW0GQR1XS
D-263MGNVLmdXBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLjTWM2OD16LkW1N|k3KM7:TR?=Ml7YV2FPT0WU
NCI-H209Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRThwNkSwNFYh|ryPNGC2SodUSU6JRWK=
IST-SL1M4O0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRThwOEm4PVIh|ryPNX;aZphlW0GQR1XS
ACNMlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rHbGlEPTB;OT6xPVE2PyEQvF2=NFn2b|NUSU6JRWK=
MHH-PREB-1NGjjXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTlwMkGyNVkh|ryPMojqV2FPT0WU
EW-11MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfld29RUUN3ME25MlY2Ozl4IN88US=>M1LWNnNCVkeHUh?=
KASUMI-1M1TaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;VTWM2OD17Lke4O|ch|ryPM1LaSnNCVkeHUh?=
KINGS-1NYW4NodjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTFyLkKzOFch|ryPMkHEV2FPT0WU
EVSA-TMoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjL[HdKSzVyPUGwMlMyQTJizszNMk\rV2FPT0WU
DSH1NHfKZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP2TWM2OD1zMD6zPVczKM7:TR?=NFLxbYxUSU6JRWK=
COLO-824M1XCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLUbHpbUUN3ME2xNE45PjZ7IN88US=>MnnHV2FPT0WU
K052M3vOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jRXGlEPTB;MUCuPVMzOiEQvF2=NG[5eWZUSU6JRWK=
SK-MEL-2M1izR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGO1W2FKSzVyPUGwMlk6OzlizszNMYHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro Enzyme Assays. All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.

Cell Assay: [1]

Cell lines Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
Concentrations 1 nM-10 μM
Incubation Time 2–3 days
Method Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.

Animal Study: [1]

Animal Models Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
Formulation Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
Dosages 1, 3, and 10 mg/kg
Administration Once daily by oral gavage for 3 weeks

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Galkin AV, et al. Proc Natl Acad Sci U S A, 2007, 104(1), 270-275.

[2] Katayama R, et al. Proc Natl Acad Sci U S A, 2011, 108(18), 7535-7540.

view more

Chemical Information

Download TAE684 (NVP-TAE684) SDF
Molecular Weight (MW) 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL (4.88 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 4 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related ALK Products

  • PF-06463922

    PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. Phase 1.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • GSK1838705A

    GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.

    Features:A small-molecule kinase inhibitor of IGF-1R and the insulin receptor.

  • Alectinib (CH5424802)

    Alectinib (CH5424802) is a potent ALK inhibitor with IC50 of 1.9 nM in cell-free assays, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429.

  • AP26113

    AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.

    Features:At least 10-fold more potent and selective in ALK inhibition relative to crizotinib.

  • ASP3026

    ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. Phase 1.

  • AZD3463

    AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.

  • Ceritinib (LDK378)

    Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.

    Features:Does not cross react with c-Met, and has an improved in vivo glucose homeostasis profile relative to TAE684. May be active in Crizotinib-relapsed tumors.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

Recently Viewed Items

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us